-
'Severe drought' declared in parts of UK
-
PM condemns 'chaos' as violent protests grip Albania
-
IUX Announces New Web Client Portal Built for Enhanced Browser-Based Trading
-
'I couldn't breathe', Russell Brand's alleged rape victim says
-
School roof collapse kills teacher, 32 children in NW Pakistan
-
Pope's cancer operation already reshaping papacy
-
Inter skipper Martinez facing month out with thigh injury
-
Zverev cruises past De Minaur to reach Shanghai semi-finals
-
Spanish prosecutors back abuse probe into Julio Iglesias
-
Ukraine's Zelensky defies Trump with Russian refinery strikes
-
Tech sell-off deepens as US inflation sparks AI jitters
-
Holders Australia edge New Zealand 24-22 to open Rugby league World Cup
-
Southgate does not forsee a return to management
-
'Ocarina of Time': Nintendo gives Zelda classic a modern makeover
-
Two dead as Istanbul endures heaviest rainfall in 80 years
-
France charges teen shooter citing revenge for bullying in school
-
After latest Nepal flood, survivors fear for future
-
Martinez blames 'anger' for dig at Man Utd hierarchy
-
EU leaders clash over budget as spectre of French elections looms
-
Crowds build as Albanian PM tours protest aftermath
-
'No place to breathe': life in Indonesia's fire epicentre
-
China-North Korea bridge opens, 12 years late
-
'Can't sleep': Spain's housing crunch upends lives
-
Asian Cup in Saudi Arabia could be postponed but 'no hurry' to decide: AFC
-
Musk calls on Ukraine's Zelensky to 'go' after satellite slowdown row
-
Conrad wields axe after South Africa loss to Australia
-
Still smiling at 117, Albanian may be world's oldest woman
-
School roof collapse kills teacher, 27 children in NW Pakistan
-
Pope has 'good night' in hospital: Vatican
-
Haze turns Indonesia skies orange, shuts schools in East Timor
-
China's economy seen missing target as global shocks bite: AFP poll
-
California puts first US billionaire tax to the vote
-
Costa Rica opens jail inspired by El Salvador mega-prison
-
School headscarf ban meets resistance in Austria
-
Same-sex couple takes fight for equality to Slovakian court
-
World's top cocoa producer aims for a climate-tough bean
-
'High hopes' as Indonesian women get a football league, again
-
Why is Shell facing lawsuits over climate disasters in Brazil and the Philippines?
-
'Expectations high' for Bordeaux-Begles' Champions Cup hat-trick bid, says Depoortere
-
New four-lane bridge opens between China, North Korea
-
Rennie urges All Blacks to stay focused against 'hurting' Wallabies
-
Tech stocks lead rout after US inflation fuels rate hike bets
-
Palmeiras beat Fluminense 2-1 in Libertadores semi-final first leg
-
'No time to recover': UNDP chief sounds alarm on growing poverty after Iran war shock
-
Brewers blasts leave Dodgers on brink
-
Australia says won't let big tech have 'unfettered' access to kids
-
Tech stock lead rout after US inflation fuels rate hike bets
-
Mobile clinics battle Mongolia's childhood dental 'disaster'
-
Al-Fayed survivors say UK police missing 'bigger picture'
-
Wallabies back Meredith as playmaker for second New Zealand Test
Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11
NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bill Enright, CEO and Gemma Brown, CFO of Barinthus Biotherapeutics plc, will be presenting at this year's Investor Summit Virtual on March 11th.
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates designed to guide the immune system to overcome autoimmunity and chronic infectious diseases. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Bio. With a focused pipeline built around its proprietary platform technologies, Barinthus Bio is advancing immunotherapeutic product candidates in autoimmunity and infectious diseases, including: VTP-1000, utilizing the SNAP-Tolerance Immunotherapy (SNAP-TI) platform designed to treat people with celiac disease and VTP-300, that is utilizing the ChAdOx/MVA platform designed as a potential component of a functional cure for chronic HBV infection Further, it has license, research and development, and collaboration agreements with OUI, NIH, CanSino, CRUK; and Arbutus.
Event: Q1 Investor Summit
Presentation Time: 11:00 AM ET
Location: https://www.webcaster4.com/Webcast/Page/3082/52091
Conference Overview and Structure
The Investor Summit is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various subject matter experts, and see what your peers are doing in this market.
This quarter's event is focused on MicroCap companies who are significantly undervalued and have a near-term catalyst.
Registration for Investors
To request free registration, please go to our website (https://investorsummitgroup.com/), and click the "Registration" button.
Sponsors:
Access Newswire
PCG Advisory
QuoteMedia
AGP
MZ Group
News Compliments of ACCESS Newswire
For More Information
Please visit: https://investorsummitgroup.com/
Or, contact [email protected]
SOURCE: Barinthus Biotherapeutics plc
View the original press release on ACCESS Newswire
R.Chavez--AT